Randomized Trial of Erythropoietin During Cerebral Malaria (EPOMAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00697164|
Recruitment Status : Unknown
Verified June 2008 by Claude Bernard University.
Recruitment status was: Recruiting
First Posted : June 13, 2008
Last Update Posted : June 13, 2008
Malaria remains one of the most common life-threatening illnesses in the tropics with a dramatic toll of more than one million deaths each year. A majority of malaria cases are non-complicated and only few evolve towards severe malaria resulting from the combination of parasite-specific virulence factors and host inflammatory responses. Cerebral malaria (CM) kills more than 1 million African children each year. CM carries a fatality rate of about 20% in adults, higher in children, despite timely and adequate chemotherapy. Moreover, the more rapid clearance of parasitaemia with new antimalarial drugs is not associated with improved survival, suggesting the potential interest for adjunctive therapies in the early phase of the disease.
Cerebral malaria leading to seizure and coma is associated with severe intracranial hypertension caused by brain-swelling. Recent imaging and post-mortem findings in adult cerebral malaria have confirmed the presence of diffuse cerebral oedema with thalamic and cerebellar white matter hypoattenuation, diffuse petechial hemorrhages and symmetric ischemic changes involving the thalamus and the cerebellum. However, the nature of the pathogenetic processes leading to cerebral malaria is incompletely understood but mechanisms linking cytokines with endothelial cells activation in the cerebral microvasculature have been recently stressed. The effect of new neuroprotective therapies has not yet been investigated, although the manifestations of cerebral malaria partly share features with neurological stroke or acute non-specific neurological disorders. The hormone erythropoietin (EPO) is probably one of the more enthusiastic drugs in this area.
EPO is as a member of type I cytokine superfamily with multiple functions, including a prominent role for erythropoiesis and neuroprotection. Systematically administered EPO crosses the blood brain barrier via the abundant expression of EPO receptors at brain capillaries, and acts as an anti-apoptotic and cytoprotective cytokine. Moreover, EPO prevents inflammation by inhibiting pro-inflammatory cytokines including TNFα, preserves endothelial cells integrity and prevents blood-brain barrier permeability. We propose a randomized clinical trial to investigate the safety and efficacy of EPO in patients presenting cerebral malaria and hospitalized at Gabriel Toure hospital, Bamako, Mali, to reduce the incidence of premature death in hospitalized patients.
|Condition or disease||Intervention/treatment||Phase|
|Cerebral Malaria||Drug: Placebo Drug: Erythropoietin||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Randomized Trial of Erythropoietin to Prevent Death From Cerebral Impairment During Severe Malaria|
|Study Start Date :||October 2007|
|Estimated Primary Completion Date :||December 2008|
|Estimated Study Completion Date :||March 2009|
Placebo Comparator: 1
Patients in group I received intravenous quinine followed by oral ACT for a total period of 6 days.
Saline Admission, day 1, day 2 3 days
Patients in group II received antimalarial drug as in group I and in addition 1500U/kg/day of rHUEPO for the initial 3 days.
Erythropoietin, 1500 U/kg/day Admission, day 1, day 2 3 days
Other Name: Neorecormon
- Survival [ Time Frame: day 5 post-inclusion ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00697164
|Contact: Stephane PICOT, MD PhDemail@example.com|
|Contact: Anne-Lise BIENVENU, PharmD PhDfirstname.lastname@example.org|
|Gabriel Toure Hospital||Recruiting|
|Contact: Ogobara K DOUMBO, MD PhD 223-222-8109 email@example.com|
|Contact: Salimata KONATE, MD 223-222-8109 firstname.lastname@example.org|
|Sub-Investigator: Salimata KONATE, MD|
|Principal Investigator:||Stephane PICOT, MD PhD||Claude Bernard University, Malaria Research Unit|